Astrazeneca Pharma India Share Price Hits Fresh 52-Week Low at Rs 6,545: Key Reasons Behind the Fall
- September 25, 2026
- Posted by: Harsh Piplani
- Category: News
Astrazeneca Pharma India Share Price fell to Rs 6,547.75, down 0.62% today, and printed a fresh 52-week low of Rs 6,545. The company’s market capitalisation stands at Rs 16,472.25 crore.
Astrazeneca Pharma India Share Price moved lower on 25 September 2026, with the stock closing near the day’s bottom at Rs 6,547.75 after a decline of Rs 41.15, or 0.62%. The session also marked a fresh 52-week low at Rs 6,545, while the company’s market capitalisation stood at Rs 16,472.25 crore. For readers tracking Astrazeneca Pharma India Share Price Today, the event matters because it places the stock at a one-year low within a listed universe where valuation, earnings quality and sector comparison remain central to stock news coverage. The supplied data confirms the price event, but it does not establish a company-specific catalyst. That makes Astrazeneca Pharma India Stock News a case of verified market data first, with fundamentals and peer benchmarks providing the next layer of context. Univest continues to track such moves as part of its daily share price and stock analysis coverage.
Astrazeneca Pharma India Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 6,547.75 |
| Previous Close | Rs 6,588.9 |
| Today's Move | Rs -41.15 (-0.62%) |
| Open | Rs 6,600 |
| High | Rs 6,630 |
| Low | Rs 6,545 |
| Turnover | Rs 0.43 crore |
| Market Capitalisation | Rs 16,472.25 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,547.75. versus the previous close of Rs 6,588.9, a fall of 0.62%. The stock opened at Rs 6,600, reached Rs 6,630, touched Rs 6,545.
Astrazeneca Pharma India Share Price Today opened at Rs 6,600, reached a high of Rs 6,630 and a low of Rs 6,545, before settling at Rs 6,547.75. The previous close was Rs 6,588.90, so the stock moved Rs 41.15 lower on the day, equivalent to 0.62%. The fresh 52-week low matched the day’s low, showing that the session ended at the year’s lowest level so far. Turnover stood at Rs 0.43 crore, and the market capitalisation remained Rs 16,472.25 crore. On a percentage basis, the current price is 0.03% above the 52-week low, which places the Astrazeneca Pharma India Share Price in a narrow band around its one-year trough. For investors scanning Astrazeneca Pharma India Share Price Live updates, this is the most important price action to note today, along with the fact that the move was measured against a prior close of Rs 6,588.90 rather than a broader market narrative. Univest flags the stock because the fresh yearly low gives the latest share price news a clear event-led reference point.
This is a price-led event rather than a story with an identified external trigger, so the immediate focus shifts from the move itself to what the stock’s valuation, earnings profile and sector context reveal in the sections below.
Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 16,472.25 crore |
| P/E Ratio | 97.11x |
| P/B Ratio | 18.22x |
| ROE | 23.02% |
| ROCE | 31.24% |
| EPS | Rs 67.85 |
| Book Value Per Share | Rs 361.68 |
| Dividend Yield | 0.55% |
Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 97.11x, P/B 18.22x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.
Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 16472.25 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 97.11x, P/B at 18.22x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.55%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.49x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 97.11x |
| Benchmark Median P/E | 32.49x |
| Benchmark Average P/E | 49.3x |
| Benchmark P/E Range | 3.48x to 757.76x |
| Company P/B Ratio | 18.22x |
| Benchmark Median P/B | 2.94x |
| Company ROE | 23.02% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 31.24% |
| Benchmark Median ROCE | 13.46% |
| Company Market Capitalisation | Rs 16,472.25 crore |
| Benchmark Median Market Cap | Rs 793.62 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 97.11x, which is above the benchmark median of 32.49x, a difference of +198.89%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.7%, a difference of +96.75%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.46%, a difference of +132.1%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,595.82 | 24.08 | 2.86 | 12.35 | 11.74 |
| Concord Biotech Ltd. | CONCORDBIO | 16,311.76 | 56.12 | 7.45 | 13.54 | 18.04 |
| Glenmark Life Sciences Ltd. | ALIVUS | 16,795.75 | 27.85 | 4.82 | 18.41 | 24.61 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 16,861.5 | 48.11 | 2.38 | 5.97 | 8.69 |
| Marksans Pharma Ltd. | MARKSANS | 15,745.17 | 29.61 | 4.81 | 15.31 | 21.1 |
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 97.11x compared with the displayed peer median of 29.61x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 13.54% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 18.04%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 16,472.25 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Astrazeneca Pharma India
- Astrazeneca Pharma India Share Price touched Rs 6,545, which is the fresh 52-week low and one-year low in the supplied data.
- The stock closed at Rs 6,547.75 after falling Rs 41.15, or 0.62%, from the previous close of Rs 6,588.90.
- The company’s market capitalisation is Rs 16,472.25 crore, which places Astrazeneca Pharma India Share Price in a large listed universe within healthcare.
- P/E is 97.11 and P/B is 18.22, both above the same-industry medians of 32.49 and 2.94.
- ROE is 23.02% and ROCE is 31.24%, both above the industry medians of 11.7% and 13.46% in the supplied benchmark.
About Astrazeneca Pharma India
Astrazeneca Pharma India Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied company profile does not include business-segment detail, product mix or revenue mix, so the factual profile here stays focused on the listed classification. In market terms, Astrazeneca Pharma India Share Price is being tracked as part of India’s pharmaceutical universe, where valuation, earnings and sector benchmarking are central to stock news coverage. Univest keeps this company page aligned with the latest share price, company news and stock analysis data that are available in the source set.
Track Astrazeneca Pharma India Share Price on Univest
Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Track Astrazeneca Pharma India Share Price on Univest for live share price updates, share price news, market cap, company financials, shareholding pattern, 52-week levels and market insights. Readers can also review Astrazeneca Pharma India Share Price Today alongside valuation ratios, sector context, peer comparison and stock performance in one place. Univest is built to help users follow verified market data around Astrazeneca Pharma India Stock News, Astrazeneca Pharma India Latest News and Astrazeneca Pharma India Share Price Live movements without guesswork.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Astrazeneca Pharma India Share Price hit a fresh 52-week low?
Ans. The supplied data confirms that Astrazeneca Pharma India Share Price touched Rs 6,545, a fresh 52-week low. It does not establish a company-specific catalyst, so the event should be read as verified price action first.
What is Astrazeneca Pharma India Share Price today?
Ans. Astrazeneca Pharma India Share Price today is Rs 6,547.75, after falling Rs 41.15 or 0.62% from the previous close of Rs 6,588.90. The stock finished close to its daily low.
What was the day’s high and low for Astrazeneca Pharma India Share Price?
Ans. The stock opened at Rs 6,600, touched a high of Rs 6,630 and a low of Rs 6,545. The low matched the fresh 52-week low, which makes the day’s price action notable.
What is the market capitalisation of Astrazeneca Pharma India?
Ans. Astrazeneca Pharma India has a market capitalisation of Rs 16,472.25 crore. That places the company above the industry median market cap in the supplied sector snapshot and close to the peer cluster.
How is Astrazeneca Pharma India valued versus its sector benchmark?
Ans. The stock trades at a P/E of 97.11 and a P/B of 18.22, both above the same-industry medians of 32.49 and 2.94. Those figures show a richer valuation than the benchmark.
What do ROE and ROCE show for Astrazeneca Pharma India?
Ans. ROE stands at 23.02% and ROCE at 31.24%. Both are above the sector medians supplied in the benchmark, which provides useful context for Astrazeneca Pharma India Fundamental Analysis and stock news.
What do EPS and book value mean for Astrazeneca Pharma India Share Price?
Ans. EPS is Rs 67.85 and book value per share is Rs 361.68. EPS reflects earnings attributable to each share, while book value indicates the accounting net worth behind each share in the dataset.
Does Astrazeneca Pharma India offer a dividend yield?
Ans. Yes, the supplied dividend yield is 0.55%. That is historical yield data derived from the current share price context, and it should not be treated as a guaranteed future payout.
How does Astrazeneca Pharma India compare with listed peers?
Ans. In the supplied peer set, Astrazeneca Pharma India has the highest P/E and P/B. Its market cap is similar to several peers, while ROE and ROCE are also above most of the listed comparables.
Is Astrazeneca Pharma India part of the Healthcare sector?
Ans. Yes. Astrazeneca Pharma India belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. That sector context is important for comparing valuation, return ratios and market capitalisation with peers.
